Immunology and Microbiology
Vaccine Efficacy
100%
Severe Acute Respiratory Syndrome Coronavirus 2
71%
Vaccination Policy
42%
COVID-19
41%
Spike
38%
Omicron Coronavirus Variant
34%
Monospecific Antibody
34%
Breakthrough Infection
28%
Titer
24%
Human Immunodeficiency Virus
22%
Comorbidity
22%
Serotype
22%
Immunogenicity
18%
Immune Response
17%
Normal Human
17%
Adoptive Immunity
11%
Neutralizing Antibody
11%
Pneumococcal Vaccine
11%
Meningococcal Vaccine
11%
Booster Dose
11%
Blood Plasma
11%
Hybrid Immunity
11%
Toxoplasmosis
11%
Tetanus Vaccine
11%
Campylobacter Concisus
11%
Human Respiratory Syncytial Virus
11%
Leukocyte Activation
11%
Chemoluminescence
11%
Respiratory Burst
8%
Opsonin
8%
Polymerase Chain Reaction
7%
Mortality Rate
6%
Blocking Antibody
6%
CD4
6%
Neutrophil Granulocyte
5%
Virus Vaccine
5%
Protein Binding
5%
Hepatitis A Virus
5%
Factor H
5%
Neutrophil
5%
Innate Immune System
5%
Lower Respiratory Tract
5%
Receptor Blocking
5%
Medicine and Dentistry
Severe Acute Respiratory Syndrome Coronavirus 2
57%
COVID-19
41%
Cohort Analysis
36%
Infection
36%
COVID-19 Vaccine
34%
Human Immunodeficiency Virus
27%
Placebo
22%
Disease
21%
Immune Response
19%
Neutralizing Antibody
14%
Interferon Gamma Release Assay
14%
Omicron Coronavirus Variant
13%
Latent Tuberculosis
12%
Antiretroviral Therapy
12%
Cellular Immunity
12%
Tuberculosis
11%
Randomized Controlled Trial
11%
Camostat Mesilate
11%
Booster Dose
11%
Meningococcus Vaccine
11%
Tetanus Toxoid
11%
Hyperimmune Globulin
11%
Receptor Blocking
11%
Serotype
11%
Adolescent
11%
Cryptococcal Meningitis
11%
Immunoglobulin
11%
Highly Active Antiretroviral Therapy
11%
Human Immunodeficiency Virus 1
11%
Prospective Cohort Study
11%
Drug Use
9%
Blocking Antibody
9%
Sputum
8%
Intention-to-Treat Analysis
8%
Immunogenicity
7%
Virus Vaccine
7%
Complement Factor H
7%
Protein Binding
7%
Hepatitis A Virus
7%
COVID-19 Vaccination
7%
Odds Ratio
6%
Infusion
6%
Mortality Rate
6%
Prophylaxis
5%
Antivirus Agent
5%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
63%
SARS Coronavirus
40%
Disease
29%
Vaccination Policy
27%
Cohort Study
24%
Camostat Mesilate
22%
COVID-19 Vaccine
22%
Randomized Controlled Trial
22%
HIV
22%
Infection
21%
Coronavirinae
16%
Neutralizing Antibody
13%
Remdesivir
13%
Adverse Event
11%
Hyperimmune Globulin
11%
Human Respiratory Syncytial Virus
11%
Comorbidity
11%
Toxoplasmosis
11%
Cerebral Toxoplasmosis
11%
Tuberculosis
11%
Latent Tuberculosis
11%
Receptor
11%
Serine Proteinase
11%
Monoclonal Antibody
11%
Immunoglobulin
11%
Molnupiravir
11%
Prospective Cohort Study
11%
Vaccine
9%
Respiratory Tract
9%
Blocking Antibody
9%
Mortality Rate
8%
Antibodies
8%
Camostat
5%
All Cause Mortality
5%